G
Gabriele Amari
Researcher at Chiesi Farmaceutici S.p.A.
Publications - 46
Citations - 407
Gabriele Amari is an academic researcher from Chiesi Farmaceutici S.p.A.. The author has contributed to research in topics: Muscarinic acetylcholine receptor M3 & Alkyl. The author has an hindex of 11, co-authored 45 publications receiving 372 citations.
Papers
More filters
Journal ArticleDOI
CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.
Nadia Moretto,Paola Caruso,Raffaella Bosco,Gessica Marchini,Fiorella Pastore,Elisabetta Armani,Gabriele Amari,Andrea Rizzi,Eleonora Ghidini,Fanti Renato De,Carmelida Capaldi,Laura Carzaniga,Emilio Hirsch,Carola Buccellati,Angelo Sala,Chiara Carnini,Riccardo Patacchini,Maurizio Delcanale,Maurizio Civelli,Gino Villetti,Fabrizio Facchinetti +20 more
TL;DR: CHF6001 has the potential to be an effective topical treatment of conditions associated with pulmonary inflammation, including asthma and chronic obstructive pulmonary disease.
Patent
Fusion proteins as immunization treatments of alzheimer's disease
Silvia Ghirardi,Elisabetta Armani,Gabriele Amari,Paola Puccini,Bruno Pietro Imbimbo,Gino Villetti +5 more
TL;DR: In this paper, a fusion protein (Aβ-Hsp) is derived from the condensation of β-amyloid protein or fragment thereof with a heat shock protein (HSP) according to the following pathway: (Formula).
Journal ArticleDOI
Novel Class of Benzoic Acid Ester Derivatives as Potent PDE4 Inhibitors for Inhaled Administration in the Treatment of Respiratory Diseases
Elisabetta Armani,Gabriele Amari,Andrea Rizzi,Fanti Renato De,Eleonora Ghidini,Carmelida Capaldi,Laura Carzaniga,Paola Caruso,Matilde Guala,Ilaria Peretto,Elena La Porta,Pier Tonino Bolzoni,Fabrizio Facchinetti,Chiara Carnini,Nadia Moretto,Riccardo Patacchini,Franco Bassani,Valentina Cenacchi,Roberta Volta,Francesco Amadei,Silvia Capacchi,Maurizio Delcanale,Paola Puccini,Silvia Catinella,Maurizio Civelli,Gino Villetti +25 more
TL;DR: Through the evaluation of opportune in vitro ADME properties, a potential candidate suitable for inhaled administration in respiratory diseases was identified and tested in an in vivo model of pulmonary inflammation, proving its efficacy.
Patent
Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
TL;DR: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.
Journal ArticleDOI
Bronchodilator Activity of (3R)-3-[[[(3-fluorophenyl) [(3,4,5-trifluorophenyl)methyl]amino] carbonyl] oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a Potent, Long-Acting, and Selective Muscarinic M3 Receptor Antagonist
Gino Villetti,Fiorella Pastore,Marco Bergamaschi,Franco Bassani,Pier Tonino Bolzoni,Loredana Battipaglia,Gabriele Amari,Andrea Rizzi,Maurizio Delcanale,Roberta Volta,Valentina Cenacchi,Francesca Cacciani,Massimiliano Zaniboni,Ferruccio Berti,Giuseppe Rossoni,Selena Harrison,Paola Petrillo,Enza Santoro,Roberta Scudellaro,fabio mannini,Pierangelo Geppetti,Roberta Razzetti,Riccardo Patacchini,Maurizio Civelli +23 more
TL;DR: In conclusion, CHF5407 shows a prolonged antibronchospastic activity both in vitro and in vivo, caused by a very slow dissociation from M3 receptors.